Search the Newsreel

MiNK Therapeutics (NASDAQ:INKT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

MiNK Therapeutics (NASDAQ:INKT) reported a quarterly EPS loss of $0.62, missing analyst estimates by $0.02. The company advanced its agenT-797 treatment into a randomized Phase II ARDS trial, with preliminary data expected in the first half of 2027, and launched a paid named-patient access …

Form 8K Mink Therapeutics Inc For: 13 August By Investing.com

This article reports that Mink Therapeutics Inc. filed a Form 8K on August 13. The company's stock symbol INKT is mentioned, showing a slight increase of 2.45%. No further details about the content of the Form 8K are provided.

MiNK outlines 4-8 patients per site per month as U.S. ARDS enrollment starts in September

Earnings Call Insights: MiNK Therapeutics (INKT) Q2 2026 MANAGEMENT VIEW * "The second quarter was an important period of execution for MiNK. We moved agenT-797 into a randomized phase two study in patients with acute lung injury and ARDS." (Co-Founder, President, CEO & Director …

MiNK Therapeutics Q2 Results: Net loss narrows to $3.1M, cash at $8.8M

MiNK Therapeutics reported a narrowed net loss of $3.1 million for Q2 2026, an improvement from $4.2 million year-over-year, and ended the quarter with $8.8 million in cash. The company advanced its Agent 797 into a Phase 2 trial for acute lung injury and …

Earnings call transcript: MiNK Therapeutics narrows Q2 2026 loss as trial advances

MiNK Therapeutics reported a narrower Q2 2026 net loss of $3.1 million, or $0.62 per share, exceeding analyst expectations, and a strengthened cash position. The company is advancing its lead cell therapy, agenT-797, into a randomized Phase II study for acute lung injury, with …

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

MiNK Therapeutics (NASDAQ: INKT) announced its Q2 2026 financial results and provided an update on its randomized Phase 2 trial of agenT-797 for acute lung injury. Initial observations from the trial show treated patients were alive at Day 28 with improved oxygenation and resolution …

MiNK Therapeutics reports Phase 2 trial data for agenT-797 By Investing.com

MiNK Therapeutics (NASDAQ:INKT) announced results from its Phase 2 trial of agenT-797 for acute lung injury and acute respiratory distress syndrome. Initial observations from patients in Ukraine showed improved oxygenation, resolution of ARDS, and reduced inflammatory markers, with no major serious adverse events attributed …

Mink Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview

Mink Therapeutics Inc is projected to report a loss of 60 cents per share, as indicated in an earnings preview. The article from Reuters provides this financial expectation for the company. Full article access requires a TradingView subscription.

Transactions récentes par des initiés de Mink Therapeutics Inc. R (6Q40.F)

This article details recent insider transactions for Mink Therapeutics Inc. (6Q40.F), focusing on stock awards and sales by directors and the CEO. It presents a table of insider activities over the last two years, including transaction types, values, dates, and shares involved. The article …

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

MiNK Therapeutics (NASDAQ: INKT) announced it will report Q2 2026 financial results on Thursday, August 13, 2026, before market open. The company will host a conference call and webcast at 8:30 AM ET to review these results and provide a corporate update, specifically focusing …

Mink Therapeutics to report Q2 results, host conference call and webcast

Mink Therapeutics is scheduled to release its Q2 2026 results before the market opens on August 13, 2026. The company will also host a conference call and webcast on the same day at 8:30 a.m. ET to discuss the results, clinical updates for agenT-797, …

MiNK's First agenT-797 Patients Were Alive With Improved Oxygenation at Day 28

MiNK Therapeutics (NASDAQ: INKT) reported early positive observations from its ongoing Phase 2 trial of agenT-797 for severe hypoxemic pneumonia. The first treated patients were alive and afebrile at Day 28, showing improved oxygenation, hemodynamics, and mental status, with biomarker signals indicating immune recovery …

MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium

MiNK Therapeutics (NASDAQ: INKT) presented initial observations from its Phase 2 study of agenT-797 in patients with severe hypoxemic pneumonia at the 2026 Military Health System Research Symposium. Early findings showed treated patients were alive and afebrile at Day 28 with improved oxygenation and …

Liquidity Mapping Around (INKT) Price Events

This article analyzes Mink Therapeutics Inc. (NASDAQ: INKT) price events using AI models, highlighting a 67.3:1 risk-reward setup targeting a 19.4% gain with 0.3% risk. It identifies divergent sentiment across various time horizons and outlines three distinct institutional trading strategies: Position Trading, Momentum Breakout, …

New agenT-797 lung-injury data due from MiNK Aug. 13

MiNK Therapeutics (NASDAQ: INKT) announced it will report its Q2 2026 financial results before market open on August 13, 2026. The company will also provide clinical updates on its agenT-797 allogeneic iNKT cell therapy for acute lung injury and discuss the launch of its …

MiNK Therapeutics (INKT) Projected to Post Earnings on Thursday

MiNK Therapeutics (NASDAQ:INKT) is expected to announce its Q2 2026 earnings before market open on Thursday, August 13th, with analysts projecting a loss of $0.60 per share. The company previously surpassed expectations by reporting a $0.57 per share loss against a forecasted $0.77 loss. …

Mink Therapeutics Inc (INKT) Earnings Forecast: Future EPS & Revenue Growth Estimates

INKT Q2'26 Earnings: revenue estimate is 0 USD

MiNK Therapeutics, Inc. (INKT) is scheduled to release its Q2'26 earnings on August 12, with an expected revenue of 0 USD and an EPS of (0.60) USD. This article provides a brief overview of the upcoming earnings announcement and comparative data for previous quarters' …

Mink Therapeutics Inc (INKT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Mink Therapeutics Inc's (INKT) dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts. However, it lists multiple historical stock split events, specifically …

Mink Therapeutics Inc (INKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Mink Therapeutics Inc (INKT), detailing its support, resistance, indicators, and moving averages. It includes an overview of various technical indicators like MACD, RSI, and KDJ, alongside moving averages such as MA5 to MA200. The analysis concludes with …

Mink Therapeutics Inc (INKT) Cash Flow

This article provides a detailed cash flow statement for Mink Therapeutics Inc (INKT), offering both quarterly and annual data for operating, investing, and financing activities. It includes key financial metrics like operating cash flow, net income, and changes in working capital across multiple fiscal …

INKT|Mink Therapeutics Inc|Price:11.070|Chg%:+0.700

Mink Therapeutics Inc (INKT) closed at $11.070, up 6.75%. The company is a clinical-stage biopharmaceutical firm focusing on allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Analysts have a "Buy" rating with a target price of $39.00, suggesting a …

Mink Therapeutics Inc (INKT) Income Statement Insights

This article provides a detailed quarterly and annual income statement for Mink Therapeutics Inc (INKT), offering insights into its financial performance, including operating expenses, R&D, net income, and EPS. It also features frequently asked questions about interpreting income statements and key financial metrics for …

MiNK Therapeutics, Inc. Revenue Breakdown – FWB:6Q40

This article provides a revenue breakdown for MiNK Therapeutics, Inc. trading under the symbol FWB:6Q40 on the Frankfurt Stock Exchange. It highlights available financial information such as statements, statistics, dividends, earnings, and segment performance. The content is hosted on TradingView, a platform offering various …

Mink Therapeutics Inc (INKT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Mink Therapeutics Inc (INKT), focusing on its PE, PB, and fair value. It notes that relevant data for P/E, P/B, and P/CF ratios have not yet been disclosed by the company. The overview includes the current stock …

Mink Therapeutics Inc (INKT) Institutional Confidence

This article provides an overview of Mink Therapeutics Inc. (INKT) institutional shareholding, detailing the number of shares held and the percentage change for various institutional investors and individuals. Key shareholders include Agenus, Inc., GKCC, LLC, and Garo H. Armen, alongside others with varying changes …

Here's Why You Should Add INKT Stock to Your Portfolio Now

MiNK Therapeutics (INKT) is a biotechnology company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for various life-threatening diseases, including oncology and respiratory conditions. The company's lead candidate, agenT-797, is showing promising results in clinical trials for pneumonia, acute hypoxemic respiratory …

What date does MiNK Therapeutics, Inc.'s (INKT) report Earnings - Earnings Calendar & Announcement